Schadendorf D - Search Results

1

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.

Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, Rittgen W, Hemminki K, Becker JC, Kumar R, Schadendorf D. Ugurel S, et al. Among authors: schadendorf d. PLoS One. 2007 Feb 21;2(2):e236. doi: 10.1371/journal.pone.0000236. PLoS One. 2007. PMID: 17311103 Free PMC article.

2

Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.

Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Djukanovic D, et al. Among authors: schadendorf d. Anticancer Res. 2000 May-Jun;20(3B):2203-7. Anticancer Res. 2000. PMID: 10928178

3

Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.

Djukanovic D, Hofmann U, Sucker A, Schadendorf D. Djukanovic D, et al. Among authors: schadendorf d. Br J Dermatol. 2001 Dec;145(6):1030-1. doi: 10.1046/j.1365-2133.2001.04545.x. Br J Dermatol. 2001. PMID: 11899133 No abstract available.

4

Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival.

Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Hofmann U, et al. Among authors: schadendorf d. Br J Cancer. 2002 Jul 15;87(2):151-7. doi: 10.1038/sj.bjc.6600428. Br J Cancer. 2002. PMID: 12107834 Free PMC article.

5

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.

Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB. Becker JC, et al. Among authors: schadendorf d. Br J Cancer. 2002 Oct 7;87(8):840-5. doi: 10.1038/sj.bjc.6600521. Br J Cancer. 2002. PMID: 12373596 Free PMC article. Clinical Trial.

6

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Paschen A, et al. Among authors: schadendorf d. Int J Cancer. 2003 Mar 1;103(6):759-67. doi: 10.1002/ijc.10906. Int J Cancer. 2003. PMID: 12516095

7

Dose-dependent severe cutaneous reactions to imatinib.

Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Ugurel S, et al. Among authors: schadendorf d. Br J Cancer. 2003 Apr 22;88(8):1157-9. doi: 10.1038/sj.bjc.6600893. Br J Cancer. 2003. PMID: 12698177 Free PMC article.

8

Systemic treatment in advanced melanoma: innovative perspectives.

Ugurel S, Schadendorf D. Ugurel S, et al. Among authors: schadendorf d. Onkologie. 2003 Jun;26(3):234-8. doi: 10.1159/000071618. Onkologie. 2003. PMID: 12845207 Review.

9

Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib.

Ugurel S, Lahaye T, Hildenbrand R, Glorer E, Reiter A, Hochhaus A, Schadendorf D, Goerdt S. Ugurel S, et al. Among authors: schadendorf d. Br J Dermatol. 2003 Sep;149(3):678-9. doi: 10.1046/j.1365-2133.2003.05594.x. Br J Dermatol. 2003. PMID: 14511021 No abstract available.

10

Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients.

Ugurel S, Uhlig D, Pföhler C, Tilgen W, Schadendorf D, Reinhold U. Ugurel S, et al. Among authors: schadendorf d. Cancer Immunol Immunother. 2004 Jun;53(6):551-9. doi: 10.1007/s00262-003-0489-1. Epub 2004 Jan 16. Cancer Immunol Immunother. 2004. PMID: 14727087 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,112 results

Search Page

Filters